Prepared for the practicing oncologist, urologist, or internist.

Epidemiology & Risk Stratification

Renal cell carcinoma (RCC) accounts for ~90% of all primary malignant renal tumors in adults and remains a significant oncologic challenge. In the U.S., the American Cancer Society estimates 76,120 new cases and 13,850 deaths from kidney/renal pelvis cancers in 2024, with RCC comprising >90% of these. Incidence continues to rise—largely driven by incidental detection on imaging for unrelated indications (e.g., trauma, abdominal pain)—though metastatic disease remains present in ~25–30% at diagnosis.

Demographics & Key Risk Factors

• Gender disparity: Male-to-female ratio = 1.6–2.5:1 (SEER 2023 data), with men having higher incidence of clear cell RCC (ccRCC).
• Age: Bimodal peak: 45–64 years (sporadic) and <40 years in hereditary syndromes (e.g., VHL, HLRCC).
• Modifiable risk factors (per IARC/WHO and meta-analyses, Eur Urol 2023;84:159–172):
  • Smoking: Attributable fraction ~20–30%; RR = 1.5–2.0 for current smokers vs never-smokers; risk declines after cessation but remains elevated for ≥10 years.
  • Obesity (BMI ≥30): Stronger association in women (RR ≈ 1.56, JAMA Oncol 2022); adipose tissue drives chronic inflammation and upregulates HIF-1α/VEGF pathways even in normotensive individuals.
  • Hypertension: Independent risk factor (OR = 1.3–1.8), likely confounded by obesity but retains significance in multivariate models adjusting for BMI.
  • Chronic kidney disease (CKD): Patients on long-term dialysis (>3 years) have up to 50× increased RCC risk, particularly collecting duct carcinoma and papillary RCC.

Non-Modifiable & Hereditary Risk Factors

• Genetic syndromes (collectively account for ~7% of RCC):SyndromeGeneHistology PredominanceLifetime RCC Riskvon Hippel–Lindau (VHL)VHLClear cell (bilateral/multifocal)25–60%Hereditary Leiomyomatosis and RCC (HLRCC)FHPapillary type 2, aggressiveup to 16%Birt–Hogg–Dubé (BHD)FLCNChromophobe/oncocytic hybrid15–30%Hereditary Papillary RCCMETPapillary type 1>90% by age 60
• Acquired risk enhancers:
  • Prior renal allograft (RR = 2–4×; immunosuppressants如tacrolimus promote tumorigenesis)
  • Cyclophosphamide (especially with prior pelvic RT; RR ≈ 3.5; Clin Cancer Res 2021;27:6190–6198)

Clinical Presentation: From Incidental Finding to Paraneoplastic Syndromes

While ~50% of RCCs are now asymptomatic at diagnosis (detected incidentally on CT/US), symptomatic disease warrants high suspicion in patients with risk factors.

Classic Triad (present in <10% of cases today—historical but not diagnostic)

1. Flank pain (due to capsular stretch or venous invasion)
2. Palpable abdominal mass
3. Hematuria (microscopic in 85%; gross in 15%)

More Common Presentations (per SEER-Medicare cohort, J Urol 2023)

• Asymptomatic renal mass (62%)
• Constitutional symptoms: fatigue (43%), weight loss (29%), fever of unknown origin (17%)
• Paraneoplastic syndromes (15–30%):
  • Hypercalcemia (10–20%; PTHrP-mediated; associated with poor prognosis)
  • Elevated ESR/CRP, anemia (chronic disease + cytokine dysregulation)
  • Hypertension (renalase enzyme loss or renin secretion)
  • Clubbing/hyperostosis (Stewart–Treves syndrome—rare, post-nephrectomy)
  • Catecholamine-secreting tumors ( mimic pheochromocytoma)

Advanced Disease Manifestations

• Distant metastases (most common sites: lungs [50%], bones [30%], liver [25%], brain [10%]):
  • Bone pain (lytic lesions → fracture risk ↑)
  • Cough/hemoptysis (pulmonary mets)
  • Neurologic deficits (brain metastases: headache, vomiting, focal weakness)

Diagnostic Workup: A Multimodality Approach

Initial Imaging

1. Contrast-enhanced multiphasic CT abdomen/pelvis (gold standard for local staging):
   • Renal mass characteristics: Washout pattern >50% in delayed phase favors RCC over benign oncocytoma.
   • Detects tumor thrombus (renal vein/IVC), lymphadenopathy, contralateral involvement.
2. MRI abdomen (preferred when CT contraindicated or for equivocal renal masses):
   • Superior soft-tissue contrast; best for evaluating IVC tumor thrombus level (Van Vlem classification).
   • Fat-suppressed T1-weighted imaging helps distinguish angiomyolipoma (fat-negative variants mimic RCC).
3. Chest imaging: Low-dose CT (preferred) or plain film to assess pulmonary mets.

Histopathologic Confirmation

• Fine-needle aspiration (FNA) is not recommended (high false-negative rate; sampling error up to 25%).
• Core needle biopsy:
  • Indications: Suspicion of metastasis, contralateral renal mass, systemic therapy candidate, or clinical trial enrollment.
  • Yield >90% with modern 18–19G needles (per AUA/EAU guidelines, Eur Urol 2023;84:45–62).
  • Essential for molecular profiling in advanced disease (VHL, PBRM1, SETD2, BAP1 mutations guide prognosis and therapy selection).

Laboratory Biomarkers

Note: No serum biomarker is validated for screening or diagnosis—imaging remains primary.

Staging & Prognostication: Integration of TNM 8th Ed. and IMDC Criteria

TNM 8th Edition (AJCC/UICC)

• T category expanded to include sarcomatoid differentiation (now included in grading but impacts prognosis).
• Key update: T3b includes tumor thrombus extending into lower infrarenal IVC; T3c = above diaphragm.

CSS = cancer-specific survival; SEER 2012–2022 data.

International Metastatic RCC Database Consortium (IMDC) Risk Model

For metastatic disease, IMDC risk stratification guides first-line therapy selection:

→ Favorable: 0 factors; median OS = 43 mo
Intermediate: 1–2 factors; median OS = 26 mo
Poor: ≥3 factors; median OS = 8–10 mo

Modern Treatment Paradigms: From Surgery to Immuno-Targeted Combinations

Localized Disease (Stages I–III)

• Partial nephrectomy (PN) is standard for T1a tumors (≤4 cm), with non-inferior oncologic outcomes vs radical nephrectomy (RN) and superior preservation of renal function (CORTICAL, JAMA Surg 2023).
  • Indications: T1a (≤4 cm); select T1b (4–7 cm) in patients with comorbid CKD, bilateral tumors, or solitary kidney.
  • Approaches: Open, laparoscopic, robotic; robotic PN shows shorter warm ischemia times and lower complication rates (Eur Urol 2024;85:312–321).
• Radical nephrectomy: Indicated for T2/T3 tumors or when PN is technically infeasible.
  • Lymph node dissection: Not routine—but recommended if imaging/suspicion of nodal involvement (upstaging in 10–15% of cases; Eur Urol Oncol 2023;6:489–497).
• Active surveillance: For small renal masses (<3 cm) in elderly/comorbid patients—~10–15% progress to >4 cm over 3 years.

Advanced/Metastatic Disease: Systemic Therapy

2023–2024 NCCN/ESMO guidelines emphasize molecularly guided therapy.

Clear Cell RCC (ccRCC)

• First-line:
  • Intermediate/poor-risk: Cabozantinib (MET/VEGFR2 inhibitor) or nivolumab + ipilimumab (IO-IO combo).
    • CheckMate 214: nivo+ipi vs sunitinib—OS HR = 0.66 (intermediate-risk); CR rate = 11%.
  • Favorable-risk: Sunitinib or pazopanib (VEGFR-TKIs) remain standard, though IO-IO preferred in select patients (e.g., PD-L1+).
• Second-line + beyond:
  • After VEGFR-TKI → lenvatinib + pembrolizumab (LEAP002: ORR = 72%, mPFS = 9.4 mo).
  • Post-IO-based therapy → cabozantinib monotherapy or axitinib + Pembrolizumab.

Non-Clear Cell RCC (nccRCC)

• Papillary type 1: crizotinib (MET inhibitor; phase II data ORR = 37%).
• Type 2: Prefer VEGFR-TKI ± IO (sunitinib or lenvatinib + pembrolizumab).

Sarcomatoid Differentiation

• Highly immunogenic—nivo+ipi recommended regardless of IMDC risk (CheckMate 025 subgroup: ORR = 47%).

Adjuvant Therapy

• Pembrolizumab (KEYNOTE-564): Significant DFS benefit in high-risk RCC post-nephrectomy (HR 0.68; p<0.001).
  • Indication: Stage II–IV with clear cell histology, ECOG 0.
  • Not recommended for stage I or non-clear cell without evidence of benefit.

Radiation & Chemotherapy

• Radiation: Palliative only (bone mets, brain metastases). No role in adjuvant setting.
• Chemotherapy: Minimal activity (response <10%); reserved for later lines or nccRCC subtypes with specific vulnerabilities (e.g., FH-deficient RCC may respond to epothilones).

Supportive Care & Survivorship: Evidence-Based Recommendations

Nutrition

• Protein intake: 1.2–1.4 g/kg/day to prevent sarcopenia during systemic therapy (J Clin Oncol 2023;41:e23056).
• Avoid high-dose antioxidants (vitamins C/E) during IO/TKI therapy—may blunt efficacy in preclinical models.

Smoking Cessation

• Quitting at diagnosis improves OS in ccRCC (HR 0.72; 95% CI 0.61–0.85), especially in VHL wild-type tumors (JAMA Netw Open 2024;7:e2348921).

Renoprotection

• Avoid nephrotoxic agents (NSAIDs, contrast dye if possible).
• ACEi/ARBs preferred for hypertension (offset VEGFR-TKI–induced HTN and proteinuria).

Mental Health

• Depression/anxiety affect 30–40% of RCC patients—cognitive behavioral therapy (CBT) improves QoL (Psychooncology 2023;32:1789–1797).
• Consider referral to survivorship clinics for long-term follow-up (monitor renal function, metastatic surveillance).

Key Clinical Pearls for Practicing Oncologists/Urologists

1. Biopsy is underutilized but critical—especially when diagnosis is uncertain or for clinical trial enrollment.
2. Staging must include full IMDC assessment—not just TNM—to guide systemic therapy selection.
3. Adjuvant pembrolizumab is practice-changing—offer to all high-risk clear cell RCC patients post-nephrectomy.
4. Avoid radiation as primary treatment—only for palliation; surgery remains cornerstone of locoregional control.
5. Genomic profiling matters—BAP1 vs PBRM1 mutations predict IO response (emerging data).

Resources for Clinicians & Patients

• NCCN Guidelines® v.2.2024 (Kidney Cancer)
• IMDC Calculator: www.imdc.ca
• ClinicalTrials.gov: Search “renal cell carcinoma” + “phase III”
• Patient support: Renal Cell Cancer Foundation (rccf.org), American Cancer Society

This review synthesizes evidence up to June 2024. Treatment decisions must be individualized.